PMID- 21804080
OWN - NLM
STAT- MEDLINE
DCOM- 20110920
LR  - 20211020
IS  - 1551-5044 (Electronic)
IS  - 0022-1554 (Print)
IS  - 0022-1554 (Linking)
VI  - 59
IP  - 8
DP  - 2011 Aug
TI  - Identification of specific chondroitin sulfate species in cutaneous autoimmune 
      disease.
PG  - 780-90
LID - 10.1369/0022155411411304 [doi]
AB  - Cutaneous lupus erythematosus and dermatomyositis (DM) are chronic inflammatory 
      diseases of the skin with accumulated dermal mucin. Earlier work has shown 
      chondroitin sulfate (CS) accumulation within the dermis of discoid lupus 
      erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and DM 
      lesions compared with control skin. Immunohistochemistry for C4S revealed a 
      greater density in DLE and DM lesions, whereas SCLE lesions did not differ from 
      controls. Scleredema and scleromyxedema are attributed to increased hyaluronic 
      acid, and lesional samples from these diseases also demonstrated accumulated 
      dermal C4S. Interferon-gamma and interleukin-1alpha, but not interferon-alpha, treatment of 
      cultured dermal fibroblasts induced mRNA expression of CHST-11, which attaches 
      sulfates to the 4-position of unsulfated chondroitin. These studies on possible 
      CS core proteins revealed that serglycin, known to have C6S side chains in 
      endothelial cells, had greater density within DM dermal endothelia but not in DLE 
      or SCLE, following the pattern of C6S overexpression reported previously. CD44 
      variants expand the CS binding repertoire of the glycoprotein; CD44v7 
      co-localized to the distribution of C4S in DLE lesions, a finding not observed in 
      DM, SCLE lesions, or controls. Because C4S and C6S have immunologic effects, 
      their dysregulation in cutaneous mucinoses may contribute to the pathogenesis of 
      these disorders.
CI  - (c) The Author(s) 2011
FAU - Kim, Jessica S
AU  - Kim JS
AD  - New York University School of Medicine, New York, New York, USA.
FAU - Werth, Victoria P
AU  - Werth VP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Histochem Cytochem
JT  - The journal of histochemistry and cytochemistry : official journal of the 
      Histochemistry Society
JID - 9815334
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Interleukin-1alpha)
RN  - 0 (Proteoglycans)
RN  - 0 (RNA, Messenger)
RN  - 0 (Vesicular Transport Proteins)
RN  - 0 (serglycin)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - EC 2.8.2- (CHST11 protein, human)
RN  - EC 2.8.2.- (Sulfotransferases)
SB  - IM
MH  - Cells, Cultured
MH  - Chondroitin Sulfates/*metabolism
MH  - Dermatomyositis/*metabolism
MH  - Endothelial Cells/metabolism
MH  - Fibroblasts/drug effects/metabolism
MH  - Humans
MH  - Hyaluronan Receptors/metabolism
MH  - Immunohistochemistry
MH  - Interferon-gamma/pharmacology
MH  - Interleukin-1alpha/pharmacology
MH  - Lupus Erythematosus, Cutaneous/*metabolism
MH  - Lupus Erythematosus, Discoid/metabolism
MH  - Proteoglycans/metabolism
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Scleredema Adultorum/metabolism
MH  - Scleromyxedema/metabolism
MH  - Skin/metabolism
MH  - Sulfotransferases/genetics/metabolism
MH  - Vesicular Transport Proteins/metabolism
PMC - PMC3261606
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2011/08/02 06:00
MHDA- 2011/09/21 06:00
PMCR- 2012/08/01
CRDT- 2011/08/02 06:00
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/09/21 06:00 [medline]
PHST- 2012/08/01 00:00 [pmc-release]
AID - 59/8/780 [pii]
AID - 10.1369_0022155411411304 [pii]
AID - 10.1369/0022155411411304 [doi]
PST - ppublish
SO  - J Histochem Cytochem. 2011 Aug;59(8):780-90. doi: 10.1369/0022155411411304.